Velmanase alfa, sold under the brand name Lamzede, is a medication used for the treatment of alpha-mannosidosis.
[2] Velmanase alfa was approved for medical use in the European Union in March 2018,[3][5] and in the United States in February 2023.
[2][6] Velmanase alfa is the first enzyme replacement therapy approved in the US for the treatment of the non-central nervous system manifestations of alpha-mannosidosis.
[2] The symptoms of the disorder vary, but often include mild to moderate intellectual disability, hearing loss, weakened immune system, distinctive facial features (e.g., a large head, prominent forehead, and protruding jaw), skeletal abnormalities, and muscle weakness.
[2] The effectiveness of velmanase alfa was evaluated in participants with alpha-mannosidosis in a phase III multicenter, randomized, double-blind, placebo-controlled, parallel group study.